Clinical Trials Browser

Phase 2 × Not yet recruiting × olutasidenib × Clear all

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute